Etesevimab is a human recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor-binding domain. Etesevimab has been authorized for emergency use by the FDA for the treatment of COVID-19.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.